SME Status

Our services along the whole product lifecycle

Services by stage

Discover all our Drug Development services

Drug Development Regulatory Affairs Market Access Pharmacovigilance Quality & Compliance Case Studies

Drug Development

Drug Development Strategy Gap Analysis SME Status Orphan Drug Designation (ODD) Scientific Advice Pediatric Investigation Plan (PIP) PRIME (PRIority MEdicines) scheme CMC Regulatory solutions Clinical Trial Application (CTA) Due Diligence

Regulatory Affairs

Registration Strategy Marketing Authorization Application (MAA) CMC Regulatory solutions Dossier Development Life cycle management Due Diligence Launch readiness Advertising & Promotion

Market Access

Early Access Programs Market Access Strategy Pricing & Reimbursement Dossier Health Economic Models Negotiation with Health Authorities Pricing & Reimbursement maintenance Joint Clinical Assessment (JCA) Integrated strategy and execution in the European markets

Pharmacovigilance

QPPV Services EudraVigilance services Pharmacovigilance System Master File (PSMF) Local Pharmacovigilance

Quality & Compliance

EU INCENTIVES

In order to promote innovation in smaller companies, the European Medicines Association (EMA) supports Micro, Small and Medium-sized enterprises (SMEs) through incentives to help them overcome the main financial and administrative hurdles.

To benefit from the initiative, SME status must be assigned by EMA before a regulatory submission. Therefore, it is recommended to consider registration as an SME early during development.

NON-EU COMPANIES

Non-EEA companies can register as SMEs and indirectly benefit from the SME incentives through RPN.

Pharmaceutical & BioTech